乳腺癌放疗后早期与晚期复发的预测基因特征
研究基于两个独立队列(训练119例乳腺内复发/共343例,验证16例复发/共112例),均接受保乳术后放疗,构建并锁定预测复发时间(3年前或后)的基因特征;训练集相关系数0.85(P<1.3×10-31)、AUC 0.91,验证集相关系数0.75(P=.001)、AUC 0.92。该特征在单因素和多因素分析中均为与复发最显著相关的因素。
要点
- 41基因特征可区分放疗后3年前后的复发时间。
- 验证集灵敏度0.75、特异度1.0、阳性预测值1.0、阴性预测值0.8。
- 早期复发富集增殖与EGFR相关通路,晚期复发富集luminal与ER信号通路。
核心结论
- 乳腺癌基因特征可能识别对辅助放疗反应不佳的患者,并预测复发时间,提示可据此考虑治疗强化与随访时长。
研究设计与样本
- 研究使用两个独立患者队列,训练队列含119例乳腺内肿瘤复发患者(共343例),验证测试队列含16例复发患者(共112例)。
- 所有患者均接受保乳术后放疗;先用Spearman秩相关做初始特征选择,训练并锁定线性模型后再行测试与验证。
- 采用Cox回归进行单因素和多因素分析,并用基因集富集分析识别生物学相关概念。
主要发现
- Spearman相关识别出485个表达与复发时间(早期vs晚期)显著相关的基因,特征缩减后保留41个基因构成特征。
- 训练集中评分与复发时间相关系数0.85(P<1.3×10-31),AUC 0.91。
- 独立验证集中该特征准确识别早期与晚期复发患者:Spearman相关系数0.75(P=.001),AUC 0.92,灵敏度0.75,特异度1.0,阳性预测值1.0,阴性预测值0.8。
- 发现乳腺癌内在亚型与局部复发时间的独特关联;单因素和多因素分析中早期vs晚期复发特征均为与复发最显著相关的因素。
- 基因集富集分析显示早期复发与增殖及表皮生长因子受体概念相关,晚期复发与luminal及ER信号通路相关;敲低早期和晚期复发相关基因分别对增殖和克隆存活显示出新效应。
关键数值与推荐
- 训练集:评分与复发时间相关系数0.85(P<1.3×10-31),AUC 0.91。
- 验证集:Spearman相关系数0.75(P=.001),AUC 0.92,灵敏度0.75,特异度1.0,阳性预测值1.0,阴性预测值0.8。
- 特征基因数:初始485个显著相关基因,最终保留41个基因。
临床怎么用
- 该特征或可用于识别对辅助放疗反应不佳、易早期复发者,为治疗强化决策提供参考。
- 复发时间预测可能有助于制定乳腺癌放疗后患者的随访时长与强度。
局限性
- 验证队列复发患者仅16例(共112例),样本量有限。
- 研究为特征构建与验证,尚未报告基于该特征干预的临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Unmet clinical needs in breast cancer (BC) management include the identification of patients at high risk of local failure despite adjuvant radiation and an understanding of the biology of these recurrences. We previously reported a radiation response signature and here extend those studies to identify a signature predictive of recurrence timing (before or after 3 years). METHODS AND MATERIALS: Two independent patient cohorts were used. The training cohort included 119 patients with in-breast tumor recurrence (343 total), and the validation testing cohort had 16 patients with recurrences (112 total). All patients received radiation treatment after breast-conserving surgery. Initial feature selection used Spearman rank correlation, and a linear model was trained and locked before testing and validation. Cox regression was used for univariate and multivariable analyses (UVA and MVA, respectively). Biologically related concepts were identified using gene set enrichment analysis. RESULTS: Spearman correlation identified 485 genes whose expression was significantly associated with recurrence time (early vs late). Feature reduction further refined the list to 41 genes retained within the signature. In training, the correlation of score to recurrence time was 0.85 (P value < 1.3 × 10-31) with an area under the curve (AUC) of 0.91. Application of this early versus late signature to an independent BC testing and validation set accurately identified patients with early versus late recurrences (Spearman correlation = 0.75, P value = .001, AUC = 0.92, sensitivity = 0.75, specificity = 1.0, positive predictive value = 1.0, and negative predictive value = 0.8). Unique associations of breast cancer intrinsic subtype to timing of local recurrence were identified. In UVA and MVA the early versus late recurrence signature remained the most significant factor associated with recurrence. Gene set enrichment analysis identified proliferation and epidermal growth factor receptor concepts associated with early recurrences and luminal and ER-signaling pathways associated with late recurrences. Knockdown of genes associated with the early and late recurrences demonstrated novel effects on proliferation and clonogenic survival, respectively. CONCLUSIONS: We report a breast cancer gene signature that may identify patients unlikely to respond to adjuvant radiation and may be used to predict timing of recurrences with implications for potential treatment intensification and duration of follow-up for women with breast cancer treated with radiation.
引用
- Speers C, Chang SL, Pesch A, et al. A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. Int J Radiat Oncol Biol Phys. 2020. PMID: 32434041. doi:10.1016/j.ijrobp.2020.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。